U.S. Department of Health and Human Services
Jeffrey Kopp
 

 Contact Info

 
Tel: 301-594-3403
Email: jeffreyk@mail.nih.gov
 

 Select Experience

 
  • Consulting NephrologistMark Hatfield Clinical Research Center, NIHPresent
  • Commissioned Officer (Captain) Active Member (Rapid Deployment Force Teams PHS 1)U.S. Public Health ServicePresent
  • Adjunct Professor of MedicineUniformed Services University of the Health SciencesPresent
  • Senior InvestigatorNIDDK, NIH1995-present
  • Medical Staff FellowNIH1987-1995
  • Completed training in Internal Medicine and NephrologyUniversity of Washington1987
  • M.D.University of Pennsylvania Medical School1980
  • A.B.Harvard College1975
 

 Related Links

 

Jeffrey B. Kopp, M.D.

Chief, Kidney Diseases Branch
Senior Investigator, Kidney Diseases BranchKidney Diseases Section
Specialties
  • Clinical Research
  • Genetics/Genomics
  • Health Disparities

​Publications

A selection of recent and significant publications can be viewed below.

Publications
Kopp JB. Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens. 2013 Mar 10. [Full Text/Abstract]
Chandra P, Kopp JB. Viruses and collapsing glomerulopathy: a brief critical review. Clin Kidney J. 2013 Feb; 6:1-5. [Full Text/Abstract]
Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB, SK Investigators. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013 Jan; 83:114-20. [Full Text/Abstract]
Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011 Nov; 22:2129-37. [Full Text/Abstract]
Marasà M, Kopp JB. Monoclonal antibodies for podocytopathies: rationale and clinical responses. Nat Rev Nephrol. 2009 Jun; 5:337-48. [Full Text/Abstract]
Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008 Oct; 40:1175-84. [Full Text/Abstract]
Shrivastav S, Kino T, Cunningham T, Ichijo T, Schubert U, Heinklein P, Chrousos GP, Kopp JB. Human immunodeficiency virus (HIV)-1 viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor {gamma} and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy. Mol Endocrinol. 2008 Feb; 22:234-47. [Full Text/Abstract]
Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007 Sep; 2:906-13. [Full Text/Abstract]